Leap therapeutics presents dkn-01 monotherapy data at aacr virtual special endometrial cancer conference

Cambridge, mass., nov. 9, 2020 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its phase 2 clinical trial of dkn-01 in patients with...

LPTX Ratings Summary

LPTX Quant Ranking